Introduction {#s1}
============

*O*-GlcNAc modification, namely *O*-GlcNAcylation, is an essential post-translational modification with a single β-*N*-acetylglucosamine linked to Ser or Thr residues of various nucleocytoplasmic proteins [@pone.0063452-Torres1], [@pone.0063452-Hart1]. It contributes to various cellular cascades, including signal transduction [@pone.0063452-Wells1]--[@pone.0063452-Butkinaree1], gene expression [@pone.0063452-Comer1], [@pone.0063452-Rexach1] and protein trafficking [@pone.0063452-Kanno1]. Dysregulation in O-GlcNAcylation is assumed to be tightly linked to chronic diseases, such as cancers [@pone.0063452-Mi1]--[@pone.0063452-Lynch1], diabetes [@pone.0063452-Akimoto1] and neurodegenerative diseases [@pone.0063452-Griffith1], [@pone.0063452-Hart2].

O-GlcNAcylation is mediated by the unique pair of enzymes *O*-GlcNAc transferase (OGT) and *O*-GlcNAcase (OGA). OGT catalyzes the transfer of GlcNAc from UDP-GlcNAc to the Ser/Thr residues in a protein or peptide, while OGA is responsible for sugar removal. The human *ogt* gene is located on the X chromosome at position Xq13.1, and three variants (ncOGT, mOGT and sOGT) are produced by alternative splicing during gene expression [@pone.0063452-Hanover1]. Sequence alignment indicates that all the three OGT isoforms comprise mainly two functional regions: an N-terminal tetratricopeptide region (TPR) and a C-terminal multidomain catalytic region. The TPRs, consisting of a varied number of TPR units among different isoforms, are proposed to regulate protein-protein interactions and are associated with substrate specificity of OGT [@pone.0063452-Kreppel1]--[@pone.0063452-Kreppel2]. The C-terminal region, where the active site lies, is composed of two conservative domains: CDI and CDII [@pone.0063452-Lazarus1], [@pone.0063452-Lazarus2].

Structural information helps us get deep into the catalytic mechanism of OGT. The first line of structural information arose from a comparative study of sequence-similar proteins: phosphatase and N-GlcNAc transferase, giving a structural model for the TPR domain and catalytic domain, respectively. It is indicated that the C-terminal region of human OGT (hOGT) consists of two Rossmann-like domains and a conserved motif in the second Rossmann domain points to the UDP-GlcNAc donor binding site [@pone.0063452-Wrabl1]. In 2004, Jinek et al. reported the crystal structure of the N-terminal TPR domain of hOGT. This indicated that the TPR domain plays an important role in OGT dimerization, as well as its interaction with nup62 and other substrate proteins [@pone.0063452-Jinek1]. Later, a bacterial OGT from *Xanthomonas campestris* (*Xc*OGT) was co-crystallized with the sugar donor --UDP-GlcNAc [@pone.0063452-MartinezFleites1], [@pone.0063452-Clarke1]. The high sequence similarity between *Xc*OGT and hOGT (up to 36%) allows its application in modeling and mechanism studies for hOGT. The structure in combination with sequence alignment and site-directed mutagenesis illustrates that OGT has a conserved UDP-GlcNAc binding pocket. In hOGT, Lys842/Gln839 was involved in interactions with phosphates, while Asp925/Lys898 might interact with the nucleoside of the sugar donor. Thr202 in *Xc*OGT (corresponding to Thr560 in hOGT) was shown to form a hydrogen bond (H-bond) with the C4-OH of UDP-GlcNAc. In 2011, a truncated hOGT isoform containing the N-terminal 4.5 TPRs and the full length C-terminal domain was co-crystallized with UDP and the CKII peptide [@pone.0063452-Lazarus2]. Once again, Lys842/His498/His558 was shown to play an important role in hOGT activity. In addition, an independent mutagenesis analysis on CDI and CDII domains also indicated certain amino acids in this region play crucial roles in OGT activity [@pone.0063452-Lazarus1]. Recently, mechanism studies for OGT have been conducted via a crystallographic snapshot method by two research groups [@pone.0063452-Lazarus3], [@pone.0063452-Schimpl1]. It was found that OGT uses a dissociative S~N~2 mechanism involving electrophilic migration of the anomeric center, which is consistent with previous studies on other glycosyltransferases [@pone.0063452-Lee1].

In the present work, we describe another way to understand the interaction between OGT and a sugar donor. A strategy combining a substrate screen with molecular docking was used to study the roles of sugar moiety in the substrate recognition of OGT. A series of UDP-GlcNAc analogs was applied to profile donor substrate specificity of sOGT, four of which could be used as donor substrates. Subsequent molecular docking and site-directed mutagenesis analysis indicated that the hydrogen bonds between some residues (Leu653 and Thr560) in the sOGT active site pocket and the hydroxyl groups at C4, C6 of UDP-GlcNAc play crucial roles in sOGT recognition of UDP-GlcNAc. The steric hindrance between the N-acyl group and Met501 and hydrophobic environment near Met501 may also participate in selective binding of UDP-GlcNAc analogs.

Results and Discussion {#s2}
======================

Profiling Sugar Donors of sOGT {#s2a}
------------------------------

Since the catalytic domain is identical for the three isoforms of OGT, they should adopt a same or similar catalytic mechanism, including sugar donor recognition. Considering the facility of the prokaryotic expression system, codon optimized sOGT was expressed in *E. coli*. It was found that codon optimization could markedly improve sOGT expression in comparison with the original gene sequence. After one-step purification, the purity of sOGT reached up to 95% (data not shown). The purified sOGT was concentrated to 1.72 mg/mL.

A library of 26 UDP-GlcNAc analogs ([Figure 1](#pone-0063452-g001){ref-type="fig"}) was applied to evaluate their availability as donor substrates of sOGT. Among these, 14 compounds were substituted at C2, 8 compounds are substituted at C6, and the rest were derived from UDP-GalNAc. Compared with the positive control (UDP-GlcNAc) and negative control (without sugar donor), 4 compounds, including UDP-GlcNPr, UDP-4-deoxy-GlcNAc, UDP-6-deoxy-GalNAc and UDP-6-deoxy-GlcNAc, could be used as active sugar donors for sOGT ([Table 1](#pone-0063452-t001){ref-type="table"}). The different yields for these analogs suggested that they might have different affinity to sOGT ([Figure 2A](#pone-0063452-g002){ref-type="fig"}). Herein, in the 14 analogs substituted at the C2 N-acyl group, only UDP-GlcNPr was active. Other compounds, either with a polar substitution or with a bulkier substitution, did not work, indicating that polarity or steric hindrance might affect their recognition by sOGT. Only UDP-6-deoxy-GlcNAc was active in the 8 analogs substituted at C6, and other substitutions with a bulkier group did not work, indicating that an enlargement change at C6 was not bearable. The configuration change of C4-OH to an equatorial bond (UDP-GalNAc) is not active, but an additional C6-deoxy modification (UDP-6-deoxy-GalNAc) made it active again. In addition, the deoxy-analog at C4 (UDP-4-deoxy-GlcNAc) also worked. The results from substrate screening suggested that C4-OH might participate in sOGT recognition of sugar donors and double changes at C4/C6-OH might have changed the spatial conformation of the parent compound and made them flexible to fit into the active site pocket of sOGT.

![Structures of UDP-GlcNAc analogs used in this work.\
14 compounds in the first panel shared the same structure with UDP-GlcNAc except the part at C2 (A). 8 compounds in the second panel were substituted at C6 (B). The rest are UDP-4-deoxy-GlcNAc and UDP-GalNAc derivatives (C). The red part indicates the difference between analog and UDP-GlcNAc.](pone.0063452.g001){#pone-0063452-g001}

![The substrate slectivity of sOGT.\
(A) The conversion ratio of sOGT with active sugar donors. All reactions were performed under the same conditions. After quenching and removal of proteins, the yields were analyzed with HPLC based on the integrated areas of the products and acceptor substrate. This histogram shows the relative activities of the mutants compared to the wild-type (WT) protein; (B) The Michaelis-Menten curve of sOGT with active sugar donors. Assays were performed using 600 µM CKII peptide and varying concentrations of sugar donors. Reactions were run at 37°C for 30 min with 76 µg of sOGT for the Km measurements. Data were analyzed by Graphpad Prism 5.](pone.0063452.g002){#pone-0063452-g002}

10.1371/journal.pone.0063452.t001

###### List of UDP-GlcNAc analogs in this study and the glycosylation yields.

![](pone.0063452.t001){#pone-0063452-t001-1}

  Entry     Donor Substrate   Yield (%)   Entry      Donor Substrate     Yield (%)
  -------- ----------------- ----------- -------- --------------------- -----------
  **1**         UDP-Glc         ND^a^     **14**       UDP-GlcNPh           \<1
  **2**         UDP-Man         ND^a^     **15**   UDP-6-deoxy-GlcNAc      85.08
  **3**        UDP-GlcN         ND^a^     **16**    UDP-GlcNAc6NH~2~       ND^a^
  **4**        UDP-Man2F        ND^a^     **17**     UDP-GlcNAc6N~3~        \<1
  **5**      UDP-Man2N~3~       ND^a^     **18**   UDP-Glucuronic Acid     ND^a^
  **6**      UDP-Glc2N~3~       ND^a^     **19**      UDP-GlcNAc6S         ND^a^
  **7**       UDP-ManNAc        ND^a^     **20**     UDP-GlcNAc6NGc        ND^a^
  **8**        UDP-GlcNS        ND^a^     **21**    UDP-GlcNAc6AcN~3~      ND^a^
  **9**       UDP-GlcNPr        49.57     **22**     UDP-GlcNAc6NPh        ND^a^
  **10**      UDP-GlcNGc         \<1      **23**   UDP-4-deoxy-GlcNAc      22.21
  **11**      UDP-GlcNAz         \<1      **24**       UDP-GalNAc           \<1
  **12**      UDP-GlcNTFA        \<1      **25**         UDP-Gal           ND^a^
  **13**      UDP-GlcNBu        ND^a^     **26**   UDP-6-deoxy-GalNAc      37.72

ND^a^: not detected.

Based on the results of substrate screening, we propose that it is stringent for the hydroxyl groups at C4 and C6 during sOGT-sugar donor recognition. In contrast, the C2 N-acyl group can bear certain substitutions, such as in UDP-GlcNPr, though bulkier or hydrophilic substitution could not be accepted. Previous works indicated that UDP-GlcNAz, UDP-GlcNAc6N~3~ and UDP-GalNAc could be used as sugar donors by hOGT [@pone.0063452-Lazarus3], [@pone.0063452-Mayer1]--[@pone.0063452-Vocadlo1]. Moreover, UDP-GlcNAz could be used in the glycosylation of nup62 and a peptide from human α-A crystallin *in vitro* or metabolized onto O-GlcNAcylated proteins *in vivo*, indicating these sugar donors should be acceptable by OGT [@pone.0063452-Boyce1], [@pone.0063452-Lubas2]. The different results in our experiment might be due to the selection of a different acceptor substrate [@pone.0063452-Shen1]. To test this, these three sugar donors were tested using an octapeptide (YAVVPVSK, derived from protein EMSY, UniProt Q7Z589) as acceptor [@pone.0063452-Vosseller1], [@pone.0063452-Wang1]. It was found that UDP-GlcNAz is active with less product yield than that of UDP-GlcNAc. However, GlcNAc6N~3~ and UDP-GalNAc were still nonreactive (data not shown), indicating sugar donor recognition of OGT is affected by acceptor substrates.

Measure of the Affinity of Sugar Donors {#s2b}
---------------------------------------

Km is an inverse measure of the substrate's affinity for an enzyme --a small Km indicates high affinity and vice versa. Compared with product yields, Km is more suitable to reflect the donor substrate affinity to sOGT. Therefore, we characterized kinetic parameters of active sugar donors, which are summarized in [Table 2](#pone-0063452-t002){ref-type="table"}. Three active sugar donors with higher yields were applied in an apparent kinetic parameters assay, using UDP-GlcNAc as a positive control. Reactions were performed with a fixed concentration of CKII peptide and varying concentrations of sugar donors. The product yield corresponding to each sugar donor was assayed by HPLC, and the data were analyzed with Graphpad Prism 5 by fitting a nonlinear regression analysis for enzyme kinetics ([Figure 2B](#pone-0063452-g002){ref-type="fig"} and [Table 2](#pone-0063452-t002){ref-type="table"}). The kinetic constants of sOGT with UDP-GlcNAc is in agreement with the value reported previously [@pone.0063452-Lazarus2]. For four active sugar donors, the Km change was consistent with the aspect of yield (*Km* ~\[UDP-GlcNAc\]~ \<\<*Km* ~\[UDP-6-deoxy-GlcNAc\]~ \<*Km* ~\[UDP-GlcNPr\]~ \<*Km* ~\[UDP-4-deoxy-GlcNAc\]~). The results further demonstrated that the substitutions at the C2 N-acyl group and C4/C6-OH could affect the affinity of the sugar donor to sOGT, and the change at C4-OH might have a more significant influence on the affinity.

10.1371/journal.pone.0063452.t002

###### Apparent kinetic parameters of active sugar donors.

![](pone.0063452.t002){#pone-0063452-t002-2}

  Kinetic Constants             UDP-GlcNAc   UDP-6-DeO-GlcNAc    UDP-GlcNPr     UDP-4-DeO-GalNAc
  ---------------------------- ------------ ------------------ --------------- ------------------
  ***Km*** **(µM)**              8.5±2.36      141.8±28.14       282.1±47.02      369.5±71.58
  ***Vmax*** **(µM •min-1)**    1.3±0.078        2.5±0.28         4.3±0.48          3.7±0.59
  ***Vmax/Km*** **(min-1)**     0.16±0.034     0.018±0.0016     0.015±0.00084    0.0099±0.00034

Modeling the Interactions between the Sugar Donor and sOGT {#s2c}
----------------------------------------------------------

Obviously, the hydroxyl group changed at C4 and C6, and the hydrophilic or bulkier substitution of the C2 N-acyl group decreased the affinity between the sugar donor and sOGT to some extent. We assume that the hydroxyl group at C4 or C6 may contribute to the binding of OGT and UDP-GlcNAc via a specific H-bond, while the space around the N-acyl group may be insufficient to seat a bulkier group or may not be suitable for the access of a hydrophilic group. To confirm this hypothesis, a molecular docking study was performed using the resolved hOGT structure (PDB ID: 3PE4). Based on the docking parameters obtained from the redocking of UDP (uridine-5′-diphosphate) with the hOGT structure [@pone.0063452-Lazarus2], a comparative study of the docking state of UDP and UDP-GlcNAc was processed, showing that UDP-GlcNAc could adopt almost the same conformation as that observed in the reported hOGT-UDP-peptide complex (the RMSD value between the UDP part of UDP-GlcNAc and co-crystal UDP was 1.54 Å; see [Figure 3A](#pone-0063452-g003){ref-type="fig"}). In this docking position, close contact was found between C4-OH and the carbonyl oxygen of Leu653, or between C6-OH and the hydroxyl group of Thr560, which renders the formation of H-bond interactions. The hydrogen bond between C4-OH and Leu653 was different from that in *Xc*OGT [@pone.0063452-MartinezFleites1], which might be due to the marked difference of the amino acid sequence between these two OGTs. In addition, two other H-bonds might have formed between C3-OH and Gly654, and between C2-acetamido and His920 ([Figure 3B](#pone-0063452-g003){ref-type="fig"}). There was not sufficient space to accommodate a bulkier group substitution in these positions. The N-acyl group of UDP-GlcNAc extended to the Met501 residue in the active site pocket, and limited space was between them ([Figure 3C](#pone-0063452-g003){ref-type="fig"}). Polarity analysis of the active site pocket indicated that the space near Met501 was mainly constituted of hydrophobic residues, indicating a hydrophobic substitution of the N-acyl group might be bearable ([Figure 3D](#pone-0063452-g003){ref-type="fig"}). The results of molecular docking might provide a reasonable interpretation for either of the changes at C4/C6-OH or at the C2 N-acyl group showing decreased affinity to sOGT.

![Molecular docking.\
(A) Co-crystal ligand UDP can be well re-docked into its own binding pocket with RMSD = 0.353 Å. After the re-docking, UDP-GlcNAc was docked into the binding pocket with the co-crystal peptides present, performing the same conformation as UDP. Red stick: co-crystal UDP in 3PE4. Green surface: surface of hydrophobic residues. Blue surface: surface of hydrophilic residues and GLY. (B) There were four possible hydrogen-bond between GlcNAc and transferase; i.e. C6-OH∼Thr560, C4-OH∼Leu653, C3-OH∼Gly654 and the C2 N-acyl group∼His920. (C) The C2-acetamido points to a hydrophobic cave constituted by Met501, Leu502 and Tyr841. (D) There were six possible hydrogen-bonds between UDP-GlcNAc and O-GlcNAc transferase with a peptide substrate. Two of them were from UDP. One was between phosphate and Lys842. The other was between phosphate and Ser21 of the peptide substrate. The yellow dashed lines show the potential hydrogen-bonds. Green surface: surface of hydrophobic residues. Blue surface: surface of hydrophilic residues and GLY. Purple line: CKII peptide. The PyMOL molecular graphics system (Version 1.3r1 Schrödinger, LLC, USA) was used to conduct polarity analysis following manufacturer's instruction [@pone.0063452-DeLano1].](pone.0063452.g003){#pone-0063452-g003}

Mutagenesis Analysis of Interactions between the Sugar Donor and sOGT {#s2d}
---------------------------------------------------------------------

To confirm the molecular docking results, mutagenesis analysis was performed for three key amino acids: Leu653, Thr560 and Met501. The first two amino acids were predicted to be responsible for forming an H-bond with the sugar moiety of UDP-GlcNAc, Thr560 via the side chain hydroxyl group, and Leu653 via its backbone carbonyl oxygen. The hOGT structure showed that Leu653 lies in a flexible loop region, suggesting a bulkier amino acid residue might potentially influence its spatial position, and break the H-bond between the carbonyl oxygen and C4-OH in the sugar donor. Based on this hypothesis, Leu653 was substituted by either amino acids with larger side chains (Tyr or Phe), or amino acids with small side chains (Val or Ile), while Thr560 was substituted by either a similar Ser or hydrophobic amino acid; e.g. Ala or Val. All the mutants (T560S, T560A, T560V, L653V, L653I, L653Y and L653F) showed decreased catalytic capability against UDP-GlcNAc in contrast to the wild type sOGT ([Figure 4A](#pone-0063452-g004){ref-type="fig"}). However, T560S showed higher catalytic capability compared with T560A or T560V, while L653V and L653I both showed higher enzymatic activity compared with L653Y or L653F. As Ser shares a similar side chain as that of Thr, T560S might still form an H-bond with UDP-GlcNAc via the hydroxyl group at C2, but T560A and T560V could not. For L653 mutants, an amino acid with a bulkier side chain (L653Y and L653F) seemed to be more influential on the spatial position of the backbone carbonyl oxygen. Combining these results with that of screening and Km values of non-hydroxyl analogs, it can be inferred that the H-bonds between these two amino acids and sugar donors might play significant roles in sOGT-sugar donor recognition.

![Mutational analysis of key amino acids in sOGT.\
HPLC analysis of the glycosylation reactions of variant sOGT mutants against UDP-GlcNAc and UDP-GlcNPr. (A) Yields of wild type sOGT and M501A, M501V, T560A, T560V,T560S, L282F, L282Y, L282V and L282I mutants against UDP-GlcNAc. All mutants sustained a great loss in enzyme activity; (B) wild type sOGT and M501A, M501V against UDP-GlcNAc and UDP-GlcNPr. The ratio of conversion rates (UDP-GlcNPr/UDP-GlcNAc) indicates the selectivity of the enzyme against UDP-GlcNPr.](pone.0063452.g004){#pone-0063452-g004}

Met501 has been predicted to be responsible for the steric hindrance. To decrease the steric hindrance between Met501 and the C2 N-acyl group, Met was substituted with amino acids with smaller side chains; i.e., Ala or Val. Both the mutants (M501A/M501V) showed decreased activity in contrast to the wild type sOGT, using either UDP-GlcNAc or UDP-GlcNPr as the sugar donors. However, the ratio of conversion rates (UDP-GlcNPr/UDP-GlcNAc), which indicates substrate selectivity of an enzyme, illustrated that both mutants were prone to use UDP-GlcNPr in contrast to UDP-GlcNAc, especially M501V ([Figure 4B](#pone-0063452-g004){ref-type="fig"}). Unfortunately, neither of the mutants showed broader substrate specificity when UDP-GlcNAc analogs substituted at C2 were used as sugar donors. The results indicate steric hindrance between M501 and the C2 N-acyl group is an influential factor in sOGT-sugar donor recognition. In a previous study of OGT inhibitors, it was also found that compounds with a short linker between the C2 N-acyl group and a fluorophore disturbed its binding to OGT, while a longer linker made it work, which is consistent with our results showing that the limit space impedes the binding of some analogs [@pone.0063452-Gross1].

Conclusions {#s2e}
-----------

O-GlcNAcylation is an important post-translational modification of proteins. OGT and OGA are the only two enzymes responsible for the sugar addition and removal, respectively. In this study, we investigated the sugar binding mechanism of sOGT and unraveled several influential factors in OGT-sugar donor recognition. This implicated that the backbone carbonyl oxygen of Leu653 and the hydroxyl group of Thr560, and especially the latter one, probably contributed to its binding to UDP-GlcNAc via hydrogen bonds. The close vicinity between Met501 and the N-acyl group and the hydrophobic environment around the N-acyl group were influential factors for sOGT recognition of some UDP-GlcNAc analogs. Our results are in keeping with recent studies [@pone.0063452-Lazarus3], [@pone.0063452-Schimpl1]. These results may help with the rational design of donor analogs or inhibitors, which could be used to detect *O*-GlcNAcylated proteins and elucidate their importance in cellular events.

Materials and Methods {#s3}
=====================

Materials {#s3a}
---------

Unless stated otherwise, all materials were purchased from Beijing Dingguo Changsheng Biotechnology Co. Ltd., China. CKII peptide (KKKYPGGSTPVSSANMM; purity\>95%) and octapeptide (YAVVPVSK; purity\>95%) were synthesized by GL Biochem (Shanghai) Ltd., China [@pone.0063452-Lubas1], [@pone.0063452-Lazarus2]. UDP-GlcNAc and its analogs, including UDP-6-deoxy-GlcNAc, UDP-GalNAc, UDP-4-deoxy-GlcNAc, UDP-6-deoxy-GalNAc, UDP-GlcNBu and UDP-GlcNPr, were prepared as previously described [@pone.0063452-Cai1]. The synthesis of other UDP-GlcNAc analogs has been reported previously [@pone.0063452-Chen1], [@pone.0063452-Muthana1].

Cloning, Expression and Purification of sOGT {#s3b}
--------------------------------------------

The human mOGT gene (GI: 2266993) codon optimized for *E. coli* heterologous expression was synthesized by GeneArt (Germany) and was cloned into pMA vector. The gene encoding sOGT was amplified from the constructed vector using the forward primer 5′-CCG[GAATTC]{.ul}ATGCATTATAAAGAAGCC-3′ and reverse primer 5′-ACGC[GTCGAC]{.ul}TGCGCTTTCGGTAACTT-3′ with restriction sites underlined. The sOGT gene was subsequently inserted into pET-28a between *EcoR* I and *Sal* I (Thermo Scientific, Life Science Research, FastDigest, USA). The recombinant vector was transformed into *E. coli* BL21 (DE3) to obtain a fusion protein with a C-terminal and N-terminal His-tag. For protein expression, 20 mL of LB medium (10 g tryptone, 5 g yeast extract and 10 g NaCl per liter) containing 35 µg/mL kanamycin was inoculated with a colony picked from the plate and grown at 37°C and 250 r.p.m. overnight. The culture was used to inoculate 1 L of LB medium that was induced with isopropyl β-D-1-thiogalactopyranoside at a final concentration of 0.05 mM until OD~600nm~ reached 0.4--0.6, and grown at 13°C and 110 r.p.m. for 20 h. Cells were harvested by centrifugation at 8,000×g for 10 min and suspended in lysis buffer (20 mM Tris-HCl, pH 7.4, 0.3 M NaCl, and 0.1% Triton-X 100). The cells were disrupted by ultra-sonication using a microtip with 45% power for 20 min (2 sec on and 4 sec off) on ice and applied to centrifugation (13000×g for 30 min) to remove precipitants. The supernatants of bacterial cell lysates were loaded onto a nickel affinity chromatography column packed with 6 mL Ni-NTA agarose (QIAGEN GmbH, Hilden, Germany), which was balanced with equilibrium buffer (20 mM Tris-HCl, pH 7.4, 0.3 M NaCl and 0.1% dithiothreitol). After washing unbounded proteins with washing buffer (30 mM, 50 mM, 80 mM and 100 mM imidazole, respectively, in 20 mM Tris-HCl, pH 7.4, 0.3 M NaCl, and 0.1% dithiothreitol), the fusion proteins were eluted with elution buffer (250 mM imidazole in 20 mM Tris-HCl, pH 7.4, 0.3 M NaCl, and 0.1% dithiothreitol). The purified protein was concentrated using a 30 kD Amicon® Ultra Centrifugal Filter Unit (Millipore, Ireland), and the buffer was changed to reaction buffer (125 mM NaCl, 1 mM EDTA, 2.5 mM THP, 20 mM Tris-HCl, pH 7.4) to remove imidazole. Protein expression and purification were analyzed by 12% SDS-PAGE. The protein concentration was determined by the Bradford method.

Screening Assay {#s3c}
---------------

The reactions were performed at 37°C for 45 min, in a total volume of 100 µL containing 200 µM CKII peptide, 1 mM UDP-GlcNAc analogs, 76 µg sOGT, 12.5 mM MgCl~2~ and buffer (125 mM NaCl, 1 mM EDTA, 2.5 mM THP, 20 mM Tris-HCl, pH 7.4). After quenching by adding an equal volume of methanol, the reaction mixtures were centrifuged at 12, 000×g for 30 min and filtered with a 0.22 µm filter. The reaction mixture (40 µL) was loaded onto a C-18 reverse-phase chromatographic column to quantify the product. The yield was analyzed based on the integrated areas of products and acceptor substrate. Each reaction was repeated at least three times.

Enzyme Assays {#s3d}
-------------

The reactions for kinetic measurements of the active sugar donor substrates were performed as described above, except that the mixture was incubated at 37°C for 30 min. The apparent kinetic parameters of active sugar donor substrates were obtained by varying UDP-GlcNAc analogs from 2.0 µM to 200.0 µM (2.0 µM, 5.0 µM, 10.0 µM, 20.0 µM, 30.0 µM, 50.0 µM, 100.0 µM and 200.0 µM) at a fixed concentration of CKII (600 µM). All reactions were then quenched by the addition of an equal volume of methanol and analyzed by HPLC, using UDP-GlcNAc as a positive control and the mixture without enzymes as a negative control. The apparent kinetic parameters were obtained by fitting the data into the Michaelis-Menten equation using Graphpad Prism 5 (LA Jolla, CA, USA). Data were expressed as mean±SD of triplicate samples from independent experiments.

Molecular Docking {#s3e}
-----------------

AutoDock 4.2 was used to perform molecular docking [@pone.0063452-Oliveira1]. We re-docked the co-crystal ligands of human O-GlcNAc transferase complex (PDB ID: 3PE4) as a training set to get rational docking parameters [@pone.0063452-Lazarus2]. The ligand UDP-GlcNAc was sketched in Sybyl-X 2.0 (Tripos, Certara Inc., USA), and 30 rounds of simulated annealing (200--700 k) was performed to find reasonable conformation for docking. Docking experiments were performed with the following parameters: grid spacing was 0.375 Å, the number of points in each dimension was set to 50, 48 and 60, the grid center was set to −19.364, 28.687 and 8.804 to make sure that whole binding pocket could be covered. Docking simulations were done using the Lamarckian genetic algorithm with: GA runs = 250, population size = 200, quaternion = 30.0 and torsion = 30.0. Other parameters were set to the default. The results were evaluated following User Guide for AutoDock 4.2 [@pone.0063452-Morris1].

Site-directed Mutagenesis {#s3f}
-------------------------

Mutation sites were predicted by molecular docking. All position information in the present work refers to the hOGT isoform 1 (UniProt O15294-3). Mutations were performed using an Easy Mutagenesis System (Beijing TransGen Biotech Co. China) according to the manufacturer's instructions. All mutation primers are shown in [Table 3](#pone-0063452-t003){ref-type="table"}. All mutants were proofed by DNA sequencing.

10.1371/journal.pone.0063452.t003

###### Site mutation primers used in this study.

![](pone.0063452.t003){#pone-0063452-t003-3}

  Mutation Site[\*](#nt102){ref-type="table-fn"}    Forward Primer[\*\*](#nt103){ref-type="table-fn"}   Reverse Primer[\*\*](#nt103){ref-type="table-fn"}
  ------------------------------------------------ --------------------------------------------------- ---------------------------------------------------
  **M501A**                                               5′CATAGC[GC]{.ul}GCTGTATCCGCTGTCTC3′                5′ATACAGC[GC]{.ul}GCTATGATGCGGATGA3′
  **M501V**                                               5′CATAGC[G]{.ul}TGCTGTATCCGCTGTCTC3′                5′ATACAGCA[C]{.ul}GCTATGATGCGGATGA3′
  **T560A**                                               5′CATCCG[G]{.ul}CCAGCCATCTGATGCAGA3′                5′ATGGCTGG[C]{.ul}CGGATGATTACCAAAA3′
  **T560V**                                               5′CATCCG[GT]{.ul}CAGCCATCTGATGCAGA3′                5′ATGGCTG[AC]{.ul}CGGATGATTACCAAAA3′
  **T560S**                                               5′CATCCGA[G]{.ul}CAGCCATCTGATGCAGA3′                5′ATGGCTG[C]{.ul}TCGGATGATTACCAAAA3′
  **L653F**                                            5′ATGTGG[T]{.ul}T[C]{.ul}GGTTATCCGGGTACAA3′         5′ATAACC[G]{.ul}A[A]{.ul}CCACATTGCCTGAATC3′
  **L653Y**                                               5′ATGTGG[TAC]{.ul}GGTTATCCGGGTACAA3′                5′ATAACC[GTA]{.ul}CCACATTGCCTGAATC3′
  **L653V**                                               5′ATGTGG[G]{.ul}TGGGTTATCCGGGTACAA3′                5′ATAACCCA[C]{.ul}CCACATTGCCTGAATC3′
  **L653I**                                            5′ATGTGG[A]{.ul}T[A]{.ul}GGTTATCCGGGTACAA3′         5′ATAACC[T]{.ul}A[T]{.ul}CCACATTGCCTGAATC3′

Corresponding to hOGT isoform 1.

Underlined base(s) indicates the mutation sites.
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